Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Phase 1
Recruiting
- Conditions
- Mild Cognitive Impairment due to Alzheimer's Disease or mild Alzheimer Disease
- Registration Number
- JPRN-jRCT2080221890
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1.Presents gradual and progressive change in memory function reported by participant or partner over more than 6 months
2.Meets criteria for MCI due to AD or Mild AD based on Free and Cued Selective Reminding score with Immediate Recall (FCSRT-IR) of greater than or equal to 16 for free recall or greater than or equal to 40 for total recall
3.Clinical Dementia Rating Scale (CDR) score of 0.5 or 1, memory box score of less than or equal to 0.5
4.Mini Mental State Examination (MMSE) score of 20-30
5.florbetapir F18 scan positive for the presence of amyloid beta
6.Women must be postmenopausal
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method